Centiva Capital’s Idexx Laboratories IDXX Stock Holding History

Centiva Capital’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,806	Closed	-$1.18M	–	1795
2025 Q1	$1.18M	Buy	2,806 +1,190	+74%	+$517K	0.04%	393
2024 Q4	$668K	Buy	1,616 +1,198	+287%	+$525K	0.01%	670
2024 Q3	$211K	Buy	+418	New	+$203K	﹤0.01%	1793
2024 Q2	–	Sell	-4,412	Closed	-$2.38M	–	2271
2024 Q1	$2.38M	Buy	+4,412	New	+$2.41M	0.06%	275
2023 Q4	–	Sell	-1,354	Closed	-$592K	–	1991
2023 Q3	$592K	Buy	+1,354	New	+$675K	0.01%	881
2023 Q1	–	Sell	-1,159	Closed	-$473K	–	1663
2022 Q4	$473K	Buy	+1,159	New	+$450K	0.01%	788
2022 Q2	–	Sell	-2,586	Closed	-$1.42M	–	1816
2022 Q1	$1.42M	Buy	+2,586	New	+$1.36M	0.03%	572
2021 Q2	–	Sell	-1,768	Closed	-$865K	–	1488
2021 Q1	$865K	Sell	1,768 -665	-27%	-$333K	0.03%	408
2020 Q4	$1.22M	Buy	+2,433	New	+$1.09M	0.05%	237

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Centiva Capital's IDXX Position: Q2 2025 in Review

Centiva Capital sold out of Idexx Laboratories (IDXX) in Q2 2025, closing a stake of 2,806 shares — an estimated $1.18M sold.

Centiva Capital first reported a position in IDXX in Q4 2020 and held it in 9 quarters. The position peaked at $2.38M in Q1 2024. 1,234 funds tracked by Wall St. Rank hold IDXX as of Q2 2025.

Centiva Capital reported no remaining Idexx Laboratories position as of Q2 2025 after selling out during the quarter.
Centiva Capital sold 2,806 Idexx Laboratories shares in Q2 2025, an estimated $1.18M.
Centiva Capital first reported a position in Idexx Laboratories in Q4 2020 and held it in 9 quarters.
Centiva Capital's Idexx Laboratories position peaked at $2.38M in Q1 2024.
1,234 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.